|
gptkbp:instanceOf
|
synthetic cannabinoid
|
|
gptkbp:actsOn
|
CB1 receptor agonist
CB2 receptor agonist
|
|
gptkbp:CASNumber
|
1185887-14-9
|
|
gptkbp:category
|
recreational drug
synthetic cannabinoid
indazole-3-carboxamide
|
|
gptkbp:chemicalFormula
|
C20H28N4O2
|
|
gptkbp:firstReported
|
gptkb:Japan
2014
|
|
gptkbp:hasSMILES
|
CC(C)[C@H](NC(=O)c1nn(CC2CCCCC2)c2ccccc12)C(=O)N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AB-CHMINACA
|
|
gptkbp:IUPACName
|
gptkb:N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
|
|
gptkbp:legal_status_in_Germany
|
Anlage II
|
|
gptkbp:legal_status_in_UK
|
gptkb:Class_B
|
|
gptkbp:legalStatus
|
Schedule I controlled substance
|
|
gptkbp:molecularWeight
|
356.47 g/mol
|
|
gptkbp:PubChem_CID
|
119025052
32055541
|
|
gptkbp:relatedTo
|
AB-FUBINACA
ADB-CHMINACA
|
|
gptkbp:routeOfAdministration
|
oral
smoked
vaporized
|
|
gptkbp:sideEffect
|
death
anxiety
paranoia
seizures
tachycardia
hallucinations
|
|
gptkbp:UNII
|
6P7U6F4K2E
|
|
gptkbp:usedFor
|
recreational drug
|
|
gptkbp:bfsParent
|
gptkb:155213-67-5
gptkb:185243-69-0
|
|
gptkbp:bfsLayer
|
7
|